Fig. 2From: The safety and tolerability of combined immune checkpoint inhibitors (anti-PD-1/PD-L1 plus anti-CTLA-4): a systematic review and meta-analysisForest plot of the incidence of TRAEs leading to discontinuation of treatment for combined immunotherapy (anti-PD-1/PD-L1 and anti-CTLA-4). a any grade TRAEs leading to discontinuation of treatment, b grade 3 or higher TRAEs leading to discontinuation of treatmentBack to article page